RecruitingPhase 3Drug trialA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineThe main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.